Currently, the main targets of anti-prostate cancer targeted drugs include androgen receptor (AR) signaling pathway inhibitors (e.g., abiraterone, enzalutamide), which play a therapeutic role by blocking testosterone synthesis or competitively inhibiting androgen binding [6,7]. Here, AR is linked to prostate carcinoma.